In Segment A, members will acquire various doses and schedules of oral ABBV-744 pill to determine Safe and sound dosing regimen. Further contributors will probably be enrolled for the identified monotherapy dosign regimen. In Segment B, members will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. https://abbv-744-and-its-impact-o91368.smblogsites.com/32027932/abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc-options